{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:00:09Z","timestamp":1648630809289},"reference-count":18,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.clinthera.2009.10.003","type":"journal-article","created":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T04:48:11Z","timestamp":1258433291000},"page":"2063-2071","source":"Crossref","is-referenced-by-count":3,"title":["Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and\/or ocular hypertension: A prospective, randomized, double-masked, active-controlled, three-period crossover pilot study"],"prefix":"10.1016","volume":"31","author":[{"given":"Sriram","family":"Sonty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas K.","family":"Mundorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.10.003_bib1","series-title":"The Glaucomas","first-page":"1425","year":"1996"},{"key":"10.1016\/j.clinthera.2009.10.003_bib2","series-title":"Clinical Practice of Glaucoma","first-page":"149","author":"Stewart","year":"1990"},{"key":"10.1016\/j.clinthera.2009.10.003_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular symptoms and signs with preserved and preservative-free glaucoma medications","volume":"17","author":"Jaenen","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.10.003_bib4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","article-title":"Prevalence of ocular surface disease in glaucoma subjects","volume":"17","author":"Leung","year":"2008","journal-title":"J Glaucoma"},{"key":"10.1016\/j.clinthera.2009.10.003_bib5","first-page":"72","article-title":"Survey assesses red eye and prostaglandin use","author":"Stewart","year":"2002","journal-title":"Rev Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.10.003_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0149-2918(04)90056-2","article-title":"A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension","volume":"26","author":"Mundorf","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2009.10.003_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1185\/030079905X36378","article-title":"Timolol LA: A double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers","volume":"21","author":"Mundorf","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2009.10.003_bib8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/00061198-199812000-00008","article-title":"Efficacy and tolerability of timolol solution once daily versus timolol gel in treating elevated intraocular pressure","volume":"7","author":"Stewart","year":"1998","journal-title":"J Glaucoma"},{"key":"10.1016\/j.clinthera.2009.10.003_bib9","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0002-9394(00)00611-5","article-title":"Differences in ocular surface irritation between timolol hemihydrate and timolol maleate","volume":"130","author":"Stewart","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.10.003_bib10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0002-9394(99)00237-8","article-title":"Efficacy and tolerability of timolol solution once daily vs timolol gel added to latanoprost","volume":"128","author":"Stewart","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.10.003_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/10807680260362696","article-title":"Blood concentrations of cyclosporine A during long-term treatment with cyclosporine A ophthalmic emulsions in patients with moderate to severe dry eye disease","volume":"18","author":"Small","year":"2002","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2009.10.003_bib12_1","series-title":"Essentials of Statistics","first-page":"205","author":"Book","year":"1978"},{"key":"10.1016\/j.clinthera.2009.10.003_bib12_2","series-title":"Essentials of Statistics","first-page":"223","author":"Book","year":"1978"},{"key":"10.1016\/j.clinthera.2009.10.003_bib12_3","series-title":"Essentials of Statistics","first-page":"234","author":"Book","year":"1978"},{"key":"10.1016\/j.clinthera.2009.10.003_bib13","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00417-008-0875-7","article-title":"Side effects of commonly used glaucoma medications: Comparison of tolerability, chance of discontinuation, and subject satisfaction","volume":"246","author":"Beckers","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.10.003_bib14","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0161-6420(96)30407-7","article-title":"Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients","volume":"103","author":"Camras","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2009.10.003_bib15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0002-9394(00)00930-2","article-title":"Washout periods for brimonidine 0.2% and latanoprost 0.005%","volume":"131","author":"Stewart","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2009.10.003_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0420.1997.tb00259.x","article-title":"Safety of beta-adrenergic blocker washout period in clinical trials","volume":"75","author":"Stroman","year":"1997","journal-title":"Acta Ophthalmol Scand"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809003488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T18:18:10Z","timestamp":1558635490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809003488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0149291809003488"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.10.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}